Role of Autophagy in Tumor Progression and Regression
- 567 Downloads
Depending on tumor type, stage, and genetic context, autophagy can play an opposite role in cancer by promoting tumor progression or regression. It is now well established that autophagy limits tumor initiation, however, it promotes the progression of well-established tumors. In the context of tumor progression and immune response, experimental evidence indicate that autophagy plays a key role in maintaining survival of tumor cells under stress condition such as hypoxia. Indeed, by activating autophagy, tumor cells are able to escape immunosurveillance by activating several overlapping mechanisms in cancer cells. Such findings have inspired significant interest to develop autophagy inhibitor molecules as an entirely new approach to cancer treatment. While much remains to be learned mechanistically, it is now widely established that modulation of this process will be an attractive avenue for future anticancer therapeutic approaches. In this chapter, we will briefly describe the role of autophagy in tumor regression in the context of inflammation, necrosis, oxidative stress and genomic instability. We will also focus on recent reports highlighting the role of autophagy in the impairment of the anti-tumor immune response. In keeping with this, we believe that targeting autophagy may represent a conceptual realm for new anti-tumor strategies aiming to block immune escape.
KeywordsAutophagy Tumor immunity Inflammation Hypoxia Tumor progression Tumor regression Tumor therapy
A part of research results presented in this chapter was generated at Luxembourg Institute of Health and Gustave Roussy Cancer Center. Research projects related to these results were funded by grants from Luxembourg Ministry of Culture, Higher Education and Research (Grant LHCE 2013 11 05); Fondation Cancer Luxembourg; FNRS Televie (7.4517.14; 7.4571.15 and 7.4664.15) and “Equipe labélisée la ligue contre le cancer”.
- Akalay, I., Janji, B., Hasmim, M., Noman, M. Z., Andre, F., De Cremoux, P., et al. (2013a). Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis. Cancer Research, 73(8), 2418–2427. doi: 10.1158/0008-5472.CAN-12-2432.CrossRefPubMedGoogle Scholar
- Baginska, J., Viry, E., Berchem, G., Poli, A., Noman, M. Z., van Moer, K., et al. (2013). Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia. Proceedings of the National Academy of Sciences of the United States of America, 110(43), 17450–17455. doi: 10.1073/pnas.1304790110.CrossRefPubMedPubMedCentralGoogle Scholar
- Gozuacik, D., Bialik, S., Raveh, T., Mitou, G., Shohat, G., Sabanay, H., et al. (2008). DAP-kinase is a mediator of endoplasmic reticulum stress-induced caspase activation and autophagic cell death. Cell Death and Differentiation, 15(12), 1875–1886. doi: 10.1038/cdd.2008.121.CrossRefPubMedGoogle Scholar
- Komatsu, M., Kurokawa, H., Waguri, S., Taguchi, K., Kobayashi, A., Ichimura, Y., et al. (2010). The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nature Cell Biology, 12(3), 213–223. doi: 10.1038/ncb2021.PubMedGoogle Scholar
- Lau, A., Wang, X. J., Zhao, F., Villeneuve, N. F., Wu, T., Jiang, T., et al. (2010). A noncanonical mechanism of Nrf2 activation by autophagy deficiency: Direct interaction between Keap1 and p62. Molecular and Cellular Biology, 30(13), 3275–3285. doi: 10.1128/MCB.00248-10.CrossRefPubMedPubMedCentralGoogle Scholar
- Noman, M. Z., Buart, S., Van Pelt, J., Richon, C., Hasmim, M., Leleu, N., et al. (2009). The cooperative induction of hypoxia-inducible factor-1 alpha and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis. Journal of Immunology, 182(6), 3510–3521. doi: 10.4049/jimmunol.0800854.CrossRefGoogle Scholar
- Noman, M. Z., Janji, B., Kaminska, B., Van Moer, K., Pierson, S., Przanowski, P., et al. (2011). Blocking hypoxia-induced autophagy in tumors restores cytotoxic T-cell activity and promotes regression. Cancer Research, 71(18), 5976–5986. doi: 10.1158/0008-5472.CAN-11-1094.CrossRefPubMedGoogle Scholar
- Stein, M., Lin, H., Jeyamohan, C., Dvorzhinski, D., Gounder, M., Bray, K., et al. (2010). Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies. The Prostate, 70(13), 1388–1394. doi: 10.1002/pros.21172.CrossRefPubMedPubMedCentralGoogle Scholar
- Thiery, J., Keefe, D., Boulant, S., Boucrot, E., Walch, M., Martinvalet, D., et al. (2011). Perforin pores in the endosomal membrane trigger the release of endocytosed granzyme B into the cytosol of target cells. Nature Immunology, 12(8), 770–777. doi: 10.1038/ni.2050.CrossRefPubMedPubMedCentralGoogle Scholar
- Thiery, J., Keefe, D., Saffarian, S., Martinvalet, D., Walch, M., Boucrot, E., et al. (2010). Perforin activates clathrin- and dynamin-dependent endocytosis, which is required for plasma membrane repair and delivery of granzyme B for granzyme-mediated apoptosis. Blood, 115(8), 1582–1593. doi: 10.1182/blood-2009-10-246116.CrossRefPubMedPubMedCentralGoogle Scholar
- Yue, Z., Jin, S., Yang, C., Levine, A. J., & Heintz, N. (2003). Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proceedings of the National Academy of Sciences of the United States of America, 100(25), 15077–15082. doi: 10.1073/pnas.2436255100.CrossRefPubMedPubMedCentralGoogle Scholar